Frontlight ResearchEarly access
Acute myeloid leukaemia trials in Lithuania
14 of 16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in LithuaniaPhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
- Where
- Vilnius
- Age
- 18 years to 75 years
- People
- 650 worldwide
- Run by
- University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00 - Phase 3Not yet taking people in LithuaniaBleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- Where
- Vilnius
- Age
- 18 years and over
- People
- 875 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00 - Phase 3Taking peopleIMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
- Where
- Kaunas
- Age
- 18 years and over
- People
- 339 worldwide
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06713837 · EU 2024-514517-35-00 - Phase 3Taking peopleA study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
- Where
- Vilnius
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 - Phase 3Taking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Kaunas, Vilnius
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - Phase 1/2Taking peopleA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Where
- Vilnius
- Age
- 30 days and over
- People
- 447 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00 - Phase 3Taking peopleCHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
- Where
- Vilnius
- Age
- Up to 64 years
- People
- 675 worldwide
- Run by
- Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 - Phase 3Taking peopleRevumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Where
- Vilnius
- Age
- 18 years and over
- People
- 448 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00 - Phase 2/3Taking peopleL-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Where
- Kaunas
- Age
- 18 years to 80 years
- People
- 312 worldwide
- Run by
- Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00 - Phase 1WithdrawnStudy to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
- Where
- Vilnius
- Age
- 18 years and over
- People
- 18 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04953897 · EU 2024-516291-16-00 - Phase 1WithdrawnStudy to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
- Where
- Vilnius
- Age
- 18 years and over
- People
- 27 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04953910 · EU 2024-516292-33-00 - Phase 3Not yet taking people in LithuaniaIvosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Where
- Vilnius
- Age
- 18 years and over
- People
- 227 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016 - Phase 2Taking peopleCHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- Where
- Vilnius
- Age
- 1 month to 18 years
- People
- 60 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01 - Phase 3Not yet taking people in LithuaniaStudying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
- Where
- Vilnius
- Age
- Up to 18 years
- People
- 170 worldwide
- Run by
- Vastra Gotaland Region
See details and how to joinNCT05477589